Bullish indicating open at $55-$60, IPO prices at $37
Scott Dreyer, the Executive Vice President and Chief Commercial Officer of Collegium Pharmaceutical , Inc. (NASDAQ:COLL), a pharmaceutical company with a market capitalization of $934 million and impressive gross profit margins of 87%, recently sold shares of the company in a series of transactions. According to InvestingPro analysis, the company currently trades below its Fair Value. According to a Form 4 filing with the Securities and Exchange Commission, Dreyer sold a total of 5,643 shares over two days. The transactions, which took place on March 6 and March 7, involved selling shares at prices ranging from $30.00 to $30.02 per share. The total value of these sales amounted to $169,299. Notably, while this insider sale occurred, InvestingPro data shows the company maintains a "GREAT" financial health score, with analysts setting price targets significantly above current levels.
The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, which Dreyer adopted on August 28, 2024. Following these transactions, Dreyer holds 142,063 shares of Collegium Pharmaceutical. For deeper insights into insider trading patterns and comprehensive analysis, including 8 additional ProTips, check out the full company report on InvestingPro.
In other recent news, Collegium Pharmaceuticals reported its fourth-quarter 2024 earnings, exceeding analyst expectations with an earnings per share (EPS) of $1.75, compared to the forecast of $1.66. The company also surpassed revenue projections, posting $181.9 million against the anticipated $179.48 million. This strong financial performance was driven by record net product revenues and significant growth in its ADHD and pain management portfolios. For the full year 2024, Collegium’s revenue reached $631.4 million, marking an 11% increase from the previous year. The company also announced its projections for 2025, expecting net product revenue between $735 million and $750 million, with adjusted EBITDA anticipated to grow by over 10%. Additionally, Collegium is planning to expand its sales force and invest in digital marketing to drive further growth. Analyst firms such as Tuohyst Securities and Piper Sandler are closely monitoring these developments, as the company continues to focus on strategic growth initiatives.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.